1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9611249
SERIAL NO

14373100

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the 1H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A C R A F S P A00181 ROMA

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Alisi, Maria Alessandra Rome, IT 23 77
Cazzolla, Nicola Albano Laziale, IT 38 153
Dragone, Patrizia Rome, IT 10 24
Furlotti, Guido Rome, IT 39 126
Mancini, Francesca Nettuno, IT 9 11
Maugeri, Caterina Rome, IT 13 30
Ombrato, Rosella San Lorenzo Del Vallo, IT 12 27

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 4, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00